WallStSmart

AstraZeneca PLC (AZN)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 69% more annual revenue ($61.37B vs $36.36B). AZN leads profitability with a 17.0% profit margin vs 13.2%. AZN appears more attractively valued with a PEG of 1.47. MDT earns a higher WallStSmart Score of 62/100 (C+).

AZN

Buy

60

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

MDT

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+13.9%)

Margin of Safety

+13.9%

Fair Value

$196.93

Current Price

$161.42

$35.51 discount

UndervaluedFair: $196.93Overvalued
MDTUndervalued (+6.2%)

Margin of Safety

+6.2%

Fair Value

$91.63

Current Price

$87.16

$4.47 discount

UndervaluedFair: $91.63Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$263.09B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
20.7%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
23.5%8/10

Strong operational efficiency at 23.5%

Free Cash FlowQuality
$2.13B8/10

Generating 2.1B in free cash flow

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$109.30B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.1%8/10

Strong operational efficiency at 22.1%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

AZN3 concerns · Avg: 3.3/10
P/E RatioValuation
25.6x4/10

Moderate valuation

EPS GrowthGrowth
2.5%4/10

2.5% earnings growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.694/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

AZN profiles as a mature stock while MDT is a value play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.57 — expect wider price swings.

MDT is growing revenue faster at 9.9% — sustainability is the question.

AZN generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (62/100 vs 60/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?